Precision Medicine in Neurodegenerative Disorders

Part II

Specificaties
Gebonden, blz. | Engels
Elsevier Science | 2023
ISBN13: 9780323855556
Rubricering
Elsevier Science e druk, 2023 9780323855556
Onderdeel van serie Handbook of Clinical Neurology
€ 289,00
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Samenvatting

Precision Medicine in Neurodegenerative Disorders, Part Two, Volume 193  in the Handbook of Clinical Neurology deals with the "How" in the reconfiguration of our approach to slow accelerated brain aging. The book rethinks  animal models on which therapies are tested, outlines the progress and expected changes in biological subtyping efforts using lysosomal, endosomal, mitochondrial, immune dysregulation, and inflammatory mechanisms of disease pathophysiology, and the growing role of microbiome in shaping disease. The volume separates the potentially disease-modifying neurorescue and neurorestoration, (e.g., gene therapy and cell replacement therapy) from true precision "medicine"–matching biology with the mechanism of intervention of interest.

Specific chapters are dedicated to the promise and challenges of extracellular vesicles for both diagnosis and treatment, the growing application of digital measures and other evaluations of clinical response, the nuts and bolts of novel adaptive clinical trial designs, and the regulatory changes needed to facilitate drug development for disease-modification purposes.

Specificaties

ISBN13:9780323855556
Taal:Engels
Bindwijze:Gebonden

Inhoudsopgave

<p>Part 3 Basic Science Development<br>1. Role of rodent models in advancing precision medicine for Parkinson disease<br>2. The allure and pitfalls of the prion-like aggregation in neurodegeneration<br>3. The shift to a proteinopenia paradigm in neurodegeneration<br>4. Disease mechanisms as subtypes: Lysosomal dysfunction in the endolysosomal Parkinson disease subtype<br>5. Disease mechanisms as subtypes: Mitochondrial and bioenergetic dysfunction <br>6. Disease mechanisms as subtypes: Immune dysfunction in Parkinson disease<br>7. Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders<br>8. Disease mechanisms as subtypes: Microbiome <br>9. LRRK2: Genetic mechanisms vs genetic subtypes <br>10. Genetic mechanism vs genetic subtypes: The example of GBA <br>11. Subtyping monogenic disorders: Huntington disease </p> <p>Part 4 Clinical Trials and Therapeutic Approaches<br>12. Disease-modifying vs symptomatic treatments: splitting over lumping<br>13. Restorative cell and gene therapies for Parkinson disease<br>14. The promise and challenges of extracellular vesicles in the diagnosis of neurodegenerative diseases<br>15. Therapeutic potential of extracellular vesicles in neurodegenerative disorders<br>16. Lessons from antiamyloid-β immunotherapies in Alzheimer disease <br>17. Lessons from immunotherapies in multiple sclerosis <br>18. Adaptive clinical trials and master protocols<br>19. Role of novel endpoints and evaluations of response in Parkinson Disease<br>20. Leveraging the regulatory framework to facilitate drug development in Parkinson disease</p>
€ 289,00
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Rubrieken

    Personen

      Trefwoorden

        Precision Medicine in Neurodegenerative Disorders